DY
Dyne Therapeutics, Inc.
DYN · NASDAQ
$17.12 -0.98% (-$0.17)
1M -34.13%
Market Cap $3.20B
P/E Ratio -
Div. Yield -
ROE 64.30%
Bulios Fair Price
$13.63
20.4% downside
Current Price
$17.12
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DYN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
43 /100
Fair P/B 4.55x
EV/EBITDA N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 56.76%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 64.30%
ROA 52.25%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 12.02x
Int. coverage -33.40x
Debt/Equity 0.03x
Stability
68 /100
Stable EPS volatility 18.49%
Profitable years 0
Beta 1.08x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DYN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John G. Cox
Employees
289
Headquarters
Waltham
Upcoming events
04 NOV
Earnings
Upcoming earnings report